Ivacaftor and lumacaftor and Mefenamic acid
Determining the interaction of Ivacaftor and lumacaftor and Mefenamic acid and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 2C9 isoenzyme. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of CYP450 2C9 by ivacaftor. The clinical relevance is unknown. MANAGEMENT: Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy. References "Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals, Cambridge, MA. "Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA. "Product Information. Orkambi (ivacaftor-lumacaftor)." Vertex Pharmaceuticals, Cambridge, MA. "Product Information. Symdeko 4-Week (ivacaftor-tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA. View all 4 references
Professional:MONITOR: Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 2C9 isoenzyme. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of CYP450 2C9 by ivacaftor. The clinical relevance is unknown.
MANAGEMENT: Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.
- "Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
- "Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
- "Product Information. Orkambi (ivacaftor-lumacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
- "Product Information. Symdeko 4-Week (ivacaftor-tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
Generic Name: ivacaftor / lumacaftor
Brand name: Orkambi
Synonyms: Lumacaftor and Ivacaftor
Generic Name: mefenamic acid
Brand name: Ponstel
Synonyms: Mefenamic Acid
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Ivacaftor and lumacaftor-Mefloquine
- Ivacaftor and lumacaftor-Mefloquine Hydrochloride
- Ivacaftor and lumacaftor-Mefoxin
- Ivacaftor and lumacaftor-Mefoxin Premixed
- Ivacaftor and lumacaftor-Mega C Acid Plus
- Ivacaftor and lumacaftor-Mega Zinc-100
- Mefenamic acid-Ivacaftor and tezacaftor
- Mefenamic acid-Ivacaftor Granules
- Mefenamic acid-Ivacaftor Tablets
- Mefenamic acid-Ivermectin
- Mefenamic acid-Ivermectin (Systemic)
- Mefenamic acid-Ivermectin Cream